HEALTHALLAFRICA
Africa: 'One Injection Protects Up to Six Months' - What Is New HIV Drug Lenacapavir?
South Africa has become the ninth African country to introduce the long-acting HIV prevention drug lenacapavir, which offers protection for up to six months. Experts are discussing its mechanism, supply-demand concerns, and challenges in developing an HIV vaccine.
Mentioned
Related Signal
Adjacent reporting
- Highly effective prevention drug arrives in South Africa, which has world’s highest HIV burden
- STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
- Could Switzerland Become the First Country to Cap Its Population?
- Ebola vaccine for Bundibugyo strain could take months before human trials
- A New Hantavirus Vaccine Is in the Works
- Three Ebola vaccines in development amid growing outbreak fears